Variability in platelet responsiveness to clopidogrel among 544 individuals
- PMID: 15653023
- DOI: 10.1016/j.jacc.2004.09.067
Variability in platelet responsiveness to clopidogrel among 544 individuals
Abstract
Objectives: We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population.
Background: Recently, a number of reports, using various definitions, have dichotomized patients who are treated with clopidogrel into a minority of "non-responders" and a majority of "responders." Such classifications imply that treatment leads to an all-or-none response, with potentially important clinical implications.
Methods: We conducted secondary post-hoc analyses of a dataset consisting of volunteers (n = 94) and patients after coronary stenting (n = 405), with heart failure (n = 25), and after stroke (n = 20).
Results: The response of subjects to clopidogrel followed a normal, bell-shaped distribution, with a mean and standard deviation of 41.9 +/- 20.8% when aggregation was induced by 5 mumol/l of adenosine diphosphate. When hyporesponsiveness and hyper-responsiveness to clopidogrel were considered to be two standard deviations less than and greater than the mean, respectively, the prevalence of hyporesponsiveness and hyper-responsiveness in these patients was 4.2% and 4.8%, respectively. Pretreatment platelet activity and clinical characteristics were not associated with responsiveness to clopidogrel.
Conclusions: Individuals receiving clopidogrel exhibit a wide variability in response that follows a normal distribution. The clinical implications of this variability are unknown but potentially are important. Clinical trials are needed to define whether hyporesponders to clopidogrel are at increased risk for thrombotic events and whether hyper-responders are at increased risk for bleeding. If so, the individualization of antiplatelet therapy, including clopidogrel dosing, may be possible in the future but will require the ability to easily and reproducibly measure responsiveness by a method that has been proven to be predictive of clinical events.
Similar articles
-
Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.Am Heart J. 2007 Mar;153(3):371-7. doi: 10.1016/j.ahj.2006.12.006. Am Heart J. 2007. PMID: 17307414
-
Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.J Am Coll Cardiol. 2006 Jan 3;47(1):27-33. doi: 10.1016/j.jacc.2005.08.058. Epub 2005 Dec 9. J Am Coll Cardiol. 2006. PMID: 16386660
-
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?J Am Coll Cardiol. 2007 Feb 13;49(6):657-66. doi: 10.1016/j.jacc.2006.10.050. Epub 2007 Jan 26. J Am Coll Cardiol. 2007. PMID: 17291930
-
Clopidogrel resistance.Heart Lung Circ. 2007;16 Suppl 3:S17-28. doi: 10.1016/j.hlc.2007.03.012. Epub 2007 Jul 3. Heart Lung Circ. 2007. PMID: 17611155 Review.
-
Variability of response to clopidogrel: possible mechanisms and clinical implications.Cardiol Rev. 2006 May-Jun;14(3):136-42. doi: 10.1097/01.crd.0000188033.11188.8e. Cardiol Rev. 2006. PMID: 16628022 Review.
Cited by
-
Adjunctive cilostazol versus high maintenance dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy.Yonsei Med J. 2013 Jan 1;54(1):34-40. doi: 10.3349/ymj.2013.54.1.34. Yonsei Med J. 2013. PMID: 23225796 Free PMC article. Clinical Trial.
-
Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.Postgrad Med J. 2006 Jun;82(968):404-10. doi: 10.1136/pgmj.2006.047696. Postgrad Med J. 2006. PMID: 16754711 Free PMC article. Clinical Trial.
-
Antiplatelet therapy in acute coronary syndromes.Curr Cardiol Rep. 2008 Jul;10(4):327-33. doi: 10.1007/s11886-008-0052-y. Curr Cardiol Rep. 2008. PMID: 18611368
-
Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting.AJNR Am J Neuroradiol. 2008 Apr;29(4):786-91. doi: 10.3174/ajnr.A0917. Epub 2008 Jan 25. AJNR Am J Neuroradiol. 2008. PMID: 18223094 Free PMC article.
-
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial.J Cardiovasc Transl Res. 2014 Feb;7(1):91-100. doi: 10.1007/s12265-013-9527-3. Epub 2013 Dec 27. J Cardiovasc Transl Res. 2014. PMID: 24371012 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical